Center for Research in Security Prices, LLC

Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes.

32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.

A new study published June 6, 2025, warns that fecal microbiota transplants may introduce microbes that hijack the host environment, potentially creating new health risks.

AB Science has received a Chinese patent for its lead compound masitinib to treat COVID-19, providing intellectual property protection until April 2041.

ClostraBio has secured new investment from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners to advance its microbiome-focused therapeutics for gut health.

Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.

Climate change has significantly extended pollen seasons across the United States, with western regions experiencing up to 20 additional freeze-free days, leading to prolonged allergy symptoms.

Dr. Ralph R. Weichselbaum, chair of Radiation and Cellular Oncology at University of Chicago, has been named the 2024 Giants of Cancer Care inductee for his groundbreaking contributions to radiation oncology.

• Datopotamab deruxtecan (Dato-DXd) showed a numerical improvement in overall survival compared to docetaxel in previously treated advanced non-small cell lung cancer (NSCLC). • The TROPION-Lung01 trial highlighted a statistically significant improvement in progression-free survival in the nonsquamous NSCLC cohort treated with Dato-DXd. • A novel biomarker, TROP2 normalized membrane ratio (NMR), may predict outcomes to Dato-DXd, potentially refining patient selection. • Dato-DXd demonstrated a manageable safety profile with fewer dose reductions and treatment discontinuations compared to docetaxel.

Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy demonstrated remarkable efficacy in a Phase I/II trial, with all 12 full-dose patients achieving improved glycemic control and meeting ADA targets for HbA1c and time-in-range.